Literature DB >> 35040516

Nasopharyngeal cancer: Incidence and prognosis of human papillomavirus and Epstein-Barr virus association at a single North American institution.

Shannon S Wu1, Bonnie Chen2, Christopher W Fleming3, Akeesha A Shah4, Christopher C Griffith4, Chaim Domb3, Chandana A Reddy3, Shauna R Campbell3, Neil M Woody3, Eric D Lamarre2, Robert R Lorenz2, Brandon L Prendes2, Joseph Scharpf2, Larissa Schwartzman5, Jessica L Geiger5, Shlomo A Koyfman3, Jamie A Ku2.   

Abstract

BACKGROUND: The prognostication of Epstein-Barr virus (EBV) and human papillomavirus (HPV) status in nasopharyngeal cancer (NPC) is unclear.
METHODS: This retrospective study analyzed NPC from 2000 to 2019.
RESULTS: Seventy-eight patients were included: 43 EBV+ , 12 HPV+ , 23 EBV- /HPV- , and 0 EBV+ /HPV+ . All p16+ tumors were also positive for HPV-CISH. Baseline characteristics were not different between groups except age, N-classification, and Karnofsky Performance Scale (KPS) (p < 0.05). For EBV+ , HPV+ , and EBV- /HPV- respectively, 3-year overall survival (OS) was 89.9%, 69.8%, and 52.5% (p = 0.006). EBV- /HPV- status was significantly associated with worse OS but not freedom from progression (FFP) on univariate analysis, and did not remain a significant predictor of OS after adjusting for KPS, age, and group stage.
CONCLUSIONS: EBV+ NPC tumors were seen in younger, healthier patients than HPV+ and EBV- tumors, and there were no cases of coinfection. The association of viral status with OS was insignificant after adjusting for KPS and age.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  Epstein-Barr virus; human papillomavirus; nasopharyngeal cancer; nasopharynx; survival outcomes

Mesh:

Substances:

Year:  2022        PMID: 35040516     DOI: 10.1002/hed.26976

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

1.  Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.

Authors:  Ling-Long Tang; Rui Guo; Ning Zhang; Bin Deng; Lei Chen; Zhi-Bin Cheng; Jing Huang; Wei-Han Hu; Shao Hui Huang; Wei-Jun Luo; Jin-Hui Liang; Yu-Ming Zheng; Fan Zhang; Yan-Ping Mao; Wen-Fei Li; Guan-Qun Zhou; Xu Liu; Yu-Pei Chen; Cheng Xu; Li Lin; Qing Liu; Xiao-Jing Du; Yuan Zhang; Ying Sun; Jun Ma
Journal:  JAMA       Date:  2022-08-23       Impact factor: 157.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.